This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) will host an Investor Day on
Aug. 1, 2013 in
New York City. Mylan CEO
Heather Bresch and the company's senior leadership team will provide an overview of Mylan's strategic vision and growth strategy for the remainder of 2013 and beyond. Executive Chairman
Robert J. Coury will lead a question-and-answer session following the presentations.
The presentations will be broadcast live via webcast beginning at
1:00 p.m. ET. The meeting is expected to conclude by
5:00 p.m. ET. In-person attendance is by invitation only.
The company intends to issue its financial results for the second quarter ended
June 30, 2013 before the market opens on Aug. 1.
To access the live webcast and view the accompanying slide presentations, visit the Investor Relations section of Mylan's website, at
http://investor.mylan.com, at least 15 minutes before the presentation is scheduled to begin; click on the webcast icon to register and download or install any necessary software. If you are unable to view the live webcast, a replay will be available after the event's conclusion for a limited period of time. In addition to the webcast, U.S. callers can access the event, in listen-only mode, at 855.452.6801 or 804.325.4850 for international callers using conference ID 19222392.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com